Tulane Cancer Center (TCC) is seeking patients to participate in a clinical trial of a new drug to treat late-stage prostate cancer. TCC is the first location in the United States to take part in this ...
LONDON – Algeta A/S said its lead product Alpharadin is on course for blockbuster status after the Phase III trial was stopped on the basis of statistically significant efficacy in the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback